Poxel Announces Participation in Two Upcoming Investor Conferences

LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for type 2 diabetes, today announced that it will be featured as a presenting company at the Roth Capital Partners 29th Annual Conference and at the Oppenheimer 27th Annual Healthcare Conference.

The Roth Capital Partners Conference is being held on March 12-17th at The Ritz Carlton hotel in Dana Point, CA. The Company will present a corporate overview on Tuesday, March 14th at 10:00 am Pacific Time in PINK Salon 5 and will be available to participate in one-on-one meetings with investors.

The 27th Annual Oppenheimer Healthcare Conference will be held on March 21-22th at the Westin Hotel New York Grand Central in New York City. The Company will present a corporate overview on Tuesday, March 21st at 1:00 pm Eastern Time in the Ambassador Room and will be available to participate in one-on-one meetings with investors. The presentation at the Oppenheimer conference will be webcast live. To access the Oppenheimer webcast, please visit the following link https://www.veracast.com/webcasts/opco/healthcare2017/26108161893.cfm. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have fully enrolled a Phase 2b clinical study in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

View source version on businesswire.com: http://www.businesswire.com/news/home/20170308006301/en/

Poxel SA
Jonae R. Barnes, +1-617-818-2985
Senior Vice President, Investor Relations and Public Relations
[email protected]
or
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May, + 49 89 2424 3494 or + 49 175 571 1562
[email protected]
or
Investor relations / Media - France
NewCap
Florent Alba/Nicolas Mérigeau, + 33 1 44 71 98 55
[email protected]

Source: Poxel SA

You May Also Be Interested In

• Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
• FIA Hails Success of Landmark INDYCAR Freedom 250 Grand Prix as Motorsport Takes Centre Stage in Washington D.C.
• Appointment of Non-Executive Directors